C2 Therapeutics Receives CE Mark for Coldplay CryoBalloon
C2 Therapeutics has received CE Mark for its Coldplay CryoBalloon Focal Ablation System.
The system directs cryoablation, a process that uses extreme cold to destroy or damage diseased tissue. Its cryotherapy diffuser is housed inside a self-sizing balloon.
The CryoBalloon has the potential to treat early Barrett’s neoplasia, which develops as a result of chronic injury from gastroesophageal reflux disease, the Redwood City, Calif.-based company says.
The product is available for commercial use initially in parts of Western Europe. — Michael Cipriano